Table 2.
PCr recovery pre- and post- therapy according to randomization and history of statin myalgia
| ID | Age (years) |
Sex | Statin Dose (mg/d) | Relative Change in PCr Recovery Time (%)* |
Myalgia pain after 4 weeks (0–10) |
Time of exercise (max 420s) |
|---|---|---|---|---|---|---|
| 1 | 62 | M | Rosuvastatin (10) | −26.0 | 0 | 190 |
| 2 | 63 | M | Simvastatin (20) | 25.4 | 0 | 420 |
| 3 | 56 | M | Simvastatin (20) | −222.6 | 0 | 230 |
| 4 | 62 | F | Simvastatin (20) | 1.5 | 0 | 420 |
| 5 | 65 | M | Atorvastatin (10) | −148.6 | 0 | 420 |
| Subgroup Median [IQR] | −26.0 [150.0] | |||||
| 6 | 69 | F | Simvastatin (20) | −115.2 | 3 | 420 |
| 7 | 52 | F | Atorvastatin (20) | 22.5 | 0 | 420 |
| 8 | 63 | M | Atorvastatin (20) | −18.9 | 3 | 300 |
| 9 | 52 | M | Simvastatin (20) | 29.1 | 0 | 340 |
| Subgroup Median [IQR] | 1.8 [92.8] | |||||
| Placebo Median [IQR] | −18.9 [137.7] | |||||
| 12 | 47 | F | Simvastatin (20) | −16.6 | 0 | 420 |
| 13 | 58 | M | Simvastatin (20) | −0.3 | 0 | 420 |
| 14 | 60 | F | Simvastatin (40) | −15.0 | 0 | 420 |
| 15 | 55 | M | Atorvastatin (10) | −105.5 | 0 | 420 |
| Subgroup Median [IQR] | −15.8 [53.4] | |||||
| 16 | 73 | M | Atorvastatin (10) | 85.6 | 0 | 420 |
| 17 | 70 | F | Rosuvastatin (5) | 42.1 | 0 | 420 |
| 18 | 52 | M | Simvastatin (20) | −25.1 | 5 | 420 |
| 19 | 58 | F | Rosuvastatin (5) | −93.7 | 3 | 390 |
| 20 | 61 | M | Rosuvastatin (20) | 13.6 | 3 | 420 |
| 21 | 56 | M | Atorvastatin (80) | 3.9 | 0 | 130 |
| Subgroup Median [IQR] | 8.8 [67.2] | |||||
|
| ||||||
| CoQ10 Median [IQR] | −7.7 [38.7] | |||||
*
The relative change in PCr recovery time was defined as 100*(baseline − follow up)/baseline).